

INFECTIVE ENDOCARDITIS

The Clinical Playbook: Diagnosis,
Intervention, and Systemic Control




In-hospital Mortality: **15–30%**

5-Year Mortality: **~40%**

Core Principle: **Multidisciplinary
Synchronization.**

The Australian Context



Incidence: **3–7 per 100,000** population per year

Urban & Coastal Zones

Healthcare-associated IE increasing via indwelling devices.

Ageing populations with degenerative valvular disease (median age >60).

PWID driving right-sided, *S. aureus* infections.

Prosthetic valves account for **10–30%** of cases.


Remote & Regional Zones



ATSI populations experience IE at rates **5–10x higher**.

Driven by immense Rheumatic Heart Disease (RHD) burden.

High prevalence of Community-Associated MRSA (CA-MRSA).



The Diagnostic Equation: Modified Duke Criteria

Definite IE

2 Major OR 1 Major + 3 Minor OR 5 Minor

Possible IE

1 Major + 1 Minor OR 3 Minor

Major Criteria

1.

1. Blood Cultures

Typical organism from ≥ 2 separate cultures, **OR** persistently positive cultures (>12 h apart or majority of ≥ 4).

2.


2. Endocardial Involvement

Echo findings (oscillating mass, abscess, prosthetic dehiscence) **OR** new valvular regurgitation.

Minor Criteria

- Predisposing heart condition or IVDU
- Fever $\geq 38^{\circ}\text{C}$
- Vascular phenomena (major emboli, Janeway lesions, mycotic aneurysm)
- Immunological phenomena (Osler nodes, Roth spots, glomerulonephritis)
- Microbiological evidence not meeting major criteria

The Golden Hours: Blood Culture Protocol



DO NOT DELAY ANTIBIOTICS in haemodynamically unstable or septic patients to obtain cultures. Draw immediately, then commence empiric therapy.

Imaging Pathway: Modality Comparison

Transthoracic Echo (TTE)

Sensitivity: 50–60% overall
(~90% for native vegetations >5 mm)

Role:
First-line for **ALL** suspected IE

Limitations:
Poor for prosthetic valves,
<5mm vegetations, abscesses,
or large body habitus




Transoesophageal Echo (TEE)

Sensitivity: 90–95% overall

Role: Mandatory if TTE is
negative/inconclusive with high
suspicion, suspected prosthetic
valve IE, complications, or *S.
aureus* bacteraemia

Limitations: Semi-invasive,
requires sedation/GA



Beyond Echo: Advanced Imaging



18F-FDG PET/CT:
Excellent for
diagnostic ambiguity
in prosthetic valve IE




CT Brain/MRI:
Routine for all *S.
aureus* IE to detect
silent embolic events or
mycotic aneurysms



Cardiac CT:
Adjunct for perivalvular
anatomy and abscess
visualization

Diverging Landscapes: Valve Pathology

Native Valve IE



Primary Drivers:

Degenerative disease, RHD, PWID.

Common Flora:

S. aureus, Viridans streptococci, *Enterococcus*.

Base Empiric Regimen:

Flucloxacillin + Gentamicin.

Surgical Threshold:

Lower likelihood of requiring surgery unless complications arise.

Prosthetic Valve IE



Primary Drivers:

Perioperative contamination (early <12 mo) or transient bacteraemia (late >12 mo).

Common Flora:

Coagulase-negative staphylococci (CoNS), *S. aureus*.

Base Empiric Regimen:

Vancomycin + Gentamicin + Rifampicin (for biofilm penetration).

Surgical Threshold:

Highly likely to require surgery. Early PVE has poor outcomes with antibiotics alone.

The Pathogen Lineup



S. aureus (30–40%)

The apex predator. Highly aggressive, high embolic risk. Common in healthcare, PWID, and CA-MRSA in ATSI communities.



Viridans Group Streptococci (15–25%)

Subacute presentation. Usually penicillin-susceptible oral flora (dental source).



S. gallolyticus (5–10%)



Red Flag: Strong association with colonic neoplasia. Colonoscopy is mandatory.



Enterococcus spp. (5–10%)

GU source, elderly patients. Requires combination synergy therapy.



HACEK Group (2–5%)

Fastidious oral organisms. Require extended incubation. First-line: Ceftriaxone.



Culture-Negative IE (5–15%)

Most commonly prior antibiotic washout. Screen for *Coxiella burnetii* (Q fever - endemic in Australia) or *Bartonella*.

Empirical Antibiotic Dashboard

Note: Prolonged IV administration required (PICC line). Adjust for renal function.

Clinical Scenario	Empirical Regimen
Native Valve (Community Acquired)	Flucloxacillin 2g IV q4h + Gentamicin 1 mg/kg IV q8h.
Native Valve (Suspected MRSA / Penicillin Anaphylaxis)	Vancomycin 15–20 mg/kg IV q8–12h (AUC-guided) ± Gentamicin.
Prosthetic Valve (Any Timing)	Vancomycin 15–20 mg/kg IV + Gentamicin 1 mg/kg IV + Rifampicin 300–450 mg PO/IV q12h. (Rifampicin for biofilm penetration).
Suspected Enterococcal IE	Ampicillin 2g IV q4h + Gentamicin 1 mg/kg IV q8h.
Injecting Drug Use (Right-Sided)	Flucloxacillin 2g IV q4h ± Gentamicin.

Directed Therapy Matrix (Bug-to-Drug)

S. aureus (MSSA)

Flucloxacillin 2g IV q4h (4–6 weeks). Prosthetic: ≥ 6 weeks + Rifampicin.

S. aureus (MRSA)

Vancomycin (AUC-guided) OR Daptomycin 8-10 mg/kg IV daily (6 weeks).

Viridans strep
(Pen MIC ≤ 0.12)

Benzylopenicillin 1.8–2.4g IV q4h (4 weeks). Prosthetic: 6 weeks.

E. faecalis

Ampicillin 2g IV q4h + Gentamicin 1 mg/kg IV q8h OR
Ampicillin + Ceftriaxone (4–6 weeks).

CoNS
(Prosthetic)

Vancomycin + Rifampicin + Gentamicin (≥ 6 weeks).

Coxiella burnetii
(Q Fever)

Doxycycline 100mg BD + Hydroxychloroquine 200mg TDS
(≥ 18 months, sometimes lifelong).



Outpatient Parenteral Antibiotic Therapy (OPAT/HITH) is highly recommended for the tail-end of IV therapy in stable patients with a PICC line.

Surgical Urgency Spectrum



40-50% of IE cases require surgery during index admission. Do not delay surgery to finish antibiotics if indications are met.

Emergency (24–48h) | HEART FAILURE

Acute severe regurgitation (aortic/mitral) causing pulmonary oedema or cardiogenic shock.
Proceed even if haemodynamically unstable.

Urgent (Days) | UNCONTROLLED INFECTION


Perivalvular abscess, fistula, persistently positive cultures (>7 days), or fungal IE (almost always requires excision).

Semi-Urgent (1–2 weeks) | EMBOLIC PREVENTION

Vegetation >10mm with prior embolic event, or vegetation >15mm with high mobility (especially anterior mitral leaflet).

Contraindication Note: Severe irreversible neurological deficit from stroke.

The Abscess Anatomy Zoom



Mechanism

Perivalvular abscesses occur in 10-40% of native and up to 60% of prosthetic valve IE. The infection burrows into the aortic annulus, directly destroying the adjacent atrioventricular (AV) node.




NEW HEART BLOCK = ABSCESS

If a patient with IE develops new first-degree AV block, bundle branch block, or complete heart block, it must be treated as an abscess extending into the conduction system until proven otherwise.

Action

Mandates urgent TEE and immediate cardiothoracic surgical review. Antibiotics alone will fail.

The Embolic Vector Map



Special Populations Dashboard



Pregnancy

Penicillins and **cephalosporins** are safe. Avoid **Doxycycline** and Fluoroquinolones.



Cardiac surgery carries high **fetal mortality** (20-30%) due to bypass hypoperfusion.



Elderly

Presentations are often **atypical** (delirium, falls, functional decline). **Validate frailty.**



Careful renal dosing required for **Gentamicin/Vancomycin** (use measured creatinine clearance).



Renal Impairment



Haemodialysis carries a 50x increased risk of IE. **Vancomycin** requires strict AUC dosing and TDM.

Monitor urinalysis for immune-complex glomerulonephritis.



Hepatic Impairment



Flucloxacillin and **Rifampicin** are **hepatotoxic**. Monitor LFTs fortnightly.

Plan perioperative correction of coagulopathy for surgical candidates.

ATSI Health Action Plan



The Burden

Age-standardised incidence is 5-10x higher in Aboriginal and Torres Strait Islander Australians, driven by catastrophic Rheumatic Heart Disease (RHD) rates.



Microbiology Shift

High prevalence of Community-Associated MRSA.

Empiric therapy must include Vancomycin or Daptomycin in these remote settings. 




Remote Logistics

4-6 weeks of IV antibiotics is highly disruptive. Utilize OPAT/HITH, Royal Flying Doctor Service (RFDS) transport, and telemedicine to minimize community disconnection.



Primary Prevention

Ensure enrolment in RHD Registers 
(regular benzathine penicillin G prophylaxis).
Integrate oral health into primary care.
Ensure culturally safe care.

PWID & Harm Reduction Protocol

Clinical Profile

- Predominantly right-sided (tricuspid) IE.
- *S. aureus* is the overwhelming culprit.
- High recurrence rate (up to 40%).



Note: Isolated right-sided MSSA IE without complications may qualify for a shorter 2-week IV antibiotic course.

Intervention Mandates

1

Needle & Syringe Programmes (NSP):

Ensure access to sterile equipment.

2

Opioid Substitution Therapy (OST):

Methadone/Buprenorphine dramatically reduces injecting frequency and recurrence.

3

Technique Counselling:

Explicitly counsel against injecting into high-risk sites (neck, groin veins).

4

Vigilance:

PWID with a persistent febrile illness require a  **zero-threshold approach for echocardiography and blood cultures.**

Dental Prophylaxis Protocol

Rule of Thumb: Prophylaxis is reserved ONLY for patients at highest risk of adverse outcomes from IE, not just those at risk of acquiring it.

Who Gets Prophylaxis? (The High-Risk Cohort)



Prosthetic heart valves or prosthetic repair material.



History of previous Infective Endocarditis.



Congenital Heart Disease (cyanotic, completely repaired <6 months, or repaired with residual defects).



Pearl: Rheumatic Heart Disease alone does NOT require dental prophylaxis under current Australian guidelines.

The Regimen



First-line:

Amoxicillin 2g PO

(Single dose, 30-60 mins pre-procedure)

Penicillin Allergy:

Clindamycin 600mg PO

OR

Cefalexin 2g PO

The Endocarditis Team Hub

Core Insight: Optimal survival is impossible without simultaneous, multi-disciplinary synchronization

